This study reveals a negative correlation between stromal CD8+ tumor-infiltrating lymphocytes (sTIL CD8+) density and chemotherapy efficacy in ER+ HER2- breast cancer, suggesting that spatial heterogeneity of the immune microenvironment has significant implications for treatment decisions in patients with intermediate recurrence scores (RS 16–25), providing new insights into optimizing personalized adjuvant chemotherapy strategies.
Literature Overview
This article, 'Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer,' published in Nature Communications, systematically investigates the spatial heterogeneity of the tumor immune microenvironment in ER+ HER2- breast cancer and its predictive value for chemotherapy response. By integrating spatial proteomic and transcriptomic data, the study identifies a decoupling between CD8+ T cells enriched in the stroma and the immune status in epithelial regions, and reveals that high sTIL CD8+ density is associated with poorer outcomes following chemotherapy in patients with intermediate recurrence scores. These findings challenge the traditional notion of 'immune-cold tumors' and suggest a need to re-evaluate the functional role of immune infiltration in ER+ subtypes.Background Knowledge
ER+ HER2- breast cancer accounts for over 70% of all breast cancer cases. Although early-stage prognosis is favorable, the risk of late recurrence remains high—particularly in the intermediate-risk group with Oncotype DX recurrence scores (RS) of 16–25—where clinical benefit from chemotherapy remains uncertain. Current decision tools based on genomic assays (e.g., Oncotype DX) fail to fully capture the complexity of the tumor immune microenvironment, leading some patients to receive unnecessary chemotherapy while others may not receive adequately intensified treatment. PD-L1 expression is generally low in ER+ subtypes, and overall tumor-infiltrating lymphocytes (TILs) are less abundant than in triple-negative or HER2+ subtypes, leading to the traditional classification of this subtype as 'immune-cold.' However, recent studies suggest that even in the context of low TIL density, the spatial distribution and functional state of immune cells may still influence prognosis and treatment response. This study leverages spatial multi-omics technologies to dissect region-specific functional states of immune cells within the tumor microenvironment, exploring their potential predictive value for chemotherapy decisions, with a particular focus on the differential roles of CD8+ T cells in stromal versus epithelial compartments.
Research Methods and Experiments
The research team performed spatial proteomic analysis on 440 ER+ HER2- breast cancer patients using tissue microarrays (TMA) and whole-slide images (WSI), combined with 5-color multiplex immunofluorescence (mIF), to quantify TIL subset densities in stromal and epithelial regions. Additionally, spatial transcriptomic sequencing was conducted on 359 patients to dissect gene expression programs under different immune microenvironment states. Unsupervised clustering identified four stromal (TME) and three epithelial (EPI) immune states, revealing moderate co-occurrence between TME-3 (immune-hot) and EPI-3 (immune-hot), yet functional decoupling between the two. Using Cox regression models, the association between immune phenotypes and invasive disease-free survival (iDFS) was evaluated, showing that only in patients with intermediate RS, high sTIL CD8+ density was significantly associated with worse outcomes in the chemotherapy group. To validate these findings, the team replicated the analysis in an independent whole-slide cohort, confirming the robustness of sTIL CD8+ density as a negative predictive biomarker for chemotherapy response.Key Conclusions and Perspectives
Research Significance and Prospects
This study overturns the traditional view of ER+ HER2- breast cancer as an 'immune-cold' tumor, revealing high heterogeneity in its immune microenvironment, particularly the negative predictive value of stromal CD8+ T cells. These findings have profound implications for drug development, suggesting that chemotherapy may exacerbate pre-existing immunosuppressive microenvironments rather than enhance anti-tumor immunity in patients with intermediate RS. Therefore, future strategies should explore chemotherapy de-escalation or combination with immune-modulating agents, such as CTLA4 or TIGIT-targeted checkpoint inhibitors.
Conclusion
By leveraging high-dimensional spatial multi-omics analysis, this study reveals the clinical value of stromal CD8+ T cell density as a negative predictive biomarker for chemotherapy in ER+ HER2- breast cancer, offering a new tool for personalized treatment in patients with intermediate recurrence scores. This finding not only challenges the established concept of 'immune-cold tumors' but also underscores the critical role of spatial immune microenvironment architecture in treatment response. From bench to bedside, this work may drive a shift in treatment decision-making from genome-driven to microenvironment-integrated assessment. Future validation of sTIL CD8+ thresholds and generalizability in larger cohorts is needed, along with exploration of its applicability in other hormone receptor-positive cancers. Clinical trials combining immunotherapy with endocrine therapy should consider incorporating sTIL stratification to optimize patient selection. This study lays the foundation for precise immune subtyping in ER+ breast cancer, marking a crucial step toward a more refined and individualized cancer care system.
